A277plasty-compared to non-infected patients-ranged from 5.4 to 54 days. Differences in populations and outcome measures in studies evaluating mortality, readmissions and costs due to SSIs associated with hip arthroplasty precluded group analysis. A representative example of results from one US study reported the average total charges (in 2006 US$) of treating SSIs in patients who underwent primary total hip arthroplasty to be $73,452 compared to $38,588 to treat non-infected patients. In addition, a UK study showed that treating MRSA infections further exacerbated outcomes, with excess mean LOS of 14 days and increased costs of £4,465 compared to non-MRSA infections in 2004. ConClusions: SSI infections after hip arthroplasty impose additional cost; an important portion of SSIs are associated with S. aureus. An unmet need for targeted preventive strategies to reduce the consequences of SSIs is highlighted.
A61 mg, resulting in ~25% greater 24-hour urinary glucose excretion. In addition, CANA 300 mg may transiently block intestinal SGLT1, delaying glucose absorption and reducing postprandial glucose. METHODS: The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of CANA 100 and 300 mg versus DAPA 10 mg using Spanish-specific utilities and cost data. Direct costs were reported in euros and an annual discount rate of 3% was applied to costs and effects. The time horizon used for the economic evaluation was 40 years to reflect the chronic nature of the disease. A randomised, controlled trial of CANA in dual therapy and an NMA were sourced for initial patient characteristics and treatment effects. Results were compared with the willingness-to-pay (WTP) threshold reported for Spain (€ 30,000/QALY). RESULTS: CANA 100 mg dominated DAPA in dual therapy, with 0.061 quality-adjusted life years (QALYs) gained. CANA 300 mg was cost-effective compared to DAPA 10 mg in dual therapy with a cost-effectiveness ratio below the WTP threshold in Spain; QALYs gained were 0.084. CONCLUSIONS: These results suggest that adding CANA 100 or 300 mg instead of DAPA 10 mg in patients inadequately controlled on metformin would result in more efficient use of healthcare resources in the Spanish setting.
The aim of the study was to estimate the budget impact of SDS vs conventional strategy (CS, only intravenous) with linezolid in Mexico, from the perspective of Instituto Mexicano del Seguro Social (IMSS). Methods: Budget impact analysis (BIA) considered direct medical costs of linezolid (intravenous and tablets), length of stay, physician visits, route of administration, laboratory and imaging tests, as well as outpatient control (unit costs extracted from IMSS sources). Costs are expressed in 2013 US$ (1US$:€ 0.719). The resource use profile was estimated by Delphi method in a panel of 10 experienced infectologists. A BIA considering two scenarios was performed: i) budget impact of use CS in 100% of cases of nosocomial pneumonia caused by GPB (15,135) and ii) budget impact of use of SDS only in candidates (7,718 cases), based on the National budget allocated to health in 2013. Results: The per-patient average treatment cost (ATC)
A367 Objectives: Montelukast 4mg (MTL-4) is a recent add-on therapy for young asthmatic children. French regulators have requested real-world evidence on effectiveness of MTL-4 in infants (6-24 months), compared to inhaled corticosteroid (ICS) therapy. National claims data (SNIIR-AM) are now available to public investigators. SNIIR-AM records exhaustive medical resource utilization of the French population, i.e. 65.4 millions. Due to the limited population of infants exposed to MTL-4 from 2010 (i.e. 78 000 children 6-24 months old), SNIIR-AM represents a good tool to investigate its effectiveness. We first tested the feasibility of such a study in a pilot phase conducted on a 1/97th representative sample of the full data set (EGB: Representative Sample of Beneficiaries), to validate identification and evaluation criteria, and to identify potential pitfalls in the methods or insufficient statistical power for groups comparison, in order to take them into account in the finalized version of the protocol. We present hereafter the main conclusions of the pilot project. MethOds: We preselected infants receiving ≥ 2 consecutive dispensations of any respiratory drugs (R03 ATC classification) and presenting an initial exacerbation within 6 months following the first dispensing. Asthma exacerbation was identified by asthma-related hospitalizations, dispensing of oral corticosteroids, addition of short-acting beta agonist to existing respiratory therapy, switch to an ICS therapy with higher dosage, or switch to nebulized CS. Results: Our sample included 1,149 infants (mean age 13 months, 64% boys). Among them, 51 and 768 were assigned to Montelukast and ICS groups, respectively. Infants with a exacerbation during the 6 months post inclusion were 78.8% and 78.4% in each group, respectively (51% and 62% for oral costicosteroids only). cOnclusiOns: The results of this pilot study support the feasibility of our SNIIR-AM project, regarding inclusion criteria and identification of outcomes. These data allowed us to finalize the SNIIR-AM study protocol that is ongoing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.